BioSpace News Archive

The Company is also participating in the 21st Annual Needham Virtual Healthcare Conference, taking place April 11-14, 2022.

Goldfinch Bio today announced that it will host a virtual event to discuss the unmet need in focal segmental glomerular sclerosis (FSGS), as well as the recently announced clinical data from TRACTION-2, the ongoing Phase 2 trial evaluating GFB-887 as a precision medicine for the treatment of FSGS. GFB-887 is a podocyte-targeting, small molecule inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5).

Aldeyra Therapeutics, Inc. today announced that it will host a Research & Development Day from 10:00 a.m. to 12:30 p.m. ET on Tuesday, March 29, 2022 in New York City.

ENDRA Life Sciences Inc. today announced that the company will report financial results for the fourth quarter of 2021 on Wednesday, March 30, 2022 after the close of trading on the U.S. financial markets.

Spago Nanomedical AB will present a poster summarizing its platform technology for precision imaging and therapy at the scientific conference ACS Spring 2022, which is held digitally on March 20-24.

BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that management will be participating in two upcoming conferences.

BioCardia®, Inc. announces the designation of a new reimbursement code for the CardiAMP® Cell Therapy procedure to transplant autologous bone marrow cells to treat heart failure from the U.S. Center for Medicare and Medicaid Services.

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2021, after the market close on Tuesday, March 29, 2022.

Evommune, Inc., a clinical stage, biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced the appointment of Kyle Carver as chief financial officer.

Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”) is a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology today reported its financial results for the fiscal year 2021 and provided an update on recent business progress.